Twenty-two orchiectomized men with progressive stage D2 prostate cancer were treated with a 3-week cycle of estramustine phosphate (EMP: from day 3 to day 21) and androgen priming (from day 1 to day 4). A partial response according to the NPCP-USA criteria was shown in 4 of 20 evaluable patients. Median progression-free survival of all patients was 24 weeks (range, 4–48) and median survival, 42 weeks (range, 4–112). Although in two cases treatment had to be stopped due to a marked increase in bone pain, no life-threatening side effects were observed. The androgen sensitivity of tumors was supported by the occurrence of increase in prostatic phosphatase and in bone pain in most patients. In this group of patients, androgen priming did not seem to potentiate the effectiveness of EMP, our results being comparable to those previously reported using EMP alone.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Alison MR, Wright NA (1981) Growth kinetics. In: Duncan W (ed) Recent results in cancer research. Prostate cancer. Springer Verlag, Berlin Heidelberg New York, p 29
Andersson L, Berlin T, Boman J, Collste L, Edsmyr F, Esposti PL, Gustafsson H, Hedlund PO, Hultgren L, Leander G, Nordle O, Norlen H, Tillgard P (1980) Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study. Scand J Urol Nephrol (Suppl) 55: 143
Benson RC Jr, Gill GM (1986) Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 9(4): 341
Benson RC, Wear JB, Gill GM (1979) Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J Urol 121: 452
Bjork P, Forsgren B, Gustafsson JA, Hogborg B (1982) Partial characterization and “quantitation” of a human prostatic estramustine-binding protein. Cancer Res 42: 1935
Coffey DS, Shimazaki J, Williams-Ashman HG (1968) Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys 124: 184
Edsmyr F, Andersson L, Könyves I (1982) Estramustine phosphate (estracyt): Experimental studies and clinical experience. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer. Williams and Wilkins, Baltimore, London, p 253
English HF, Drago JR, Santen RJ (1985) Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. Prostate 7: 41
Forsgren B, Bjork P (1984) Specific binding of estramustine to prostatic proteins. Urology (Suppl) 23 (6): 34
Forgren B, Gustafsson JA, Pousette A, Hogberg B (1979) Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 β-estradiol. Cancer Res 39: 5155
Grossman HB, Kleinert EL, Lesser ML, Herr HW, Whitmore WF Jr (1981) Androgen stimulated chemotherapy in the Dunning R-3327 prostatic adenocarcinoma. Urol Res 9: 237
Lesser B, Bruchovsky N (1973) The effect of testosterone and 5 alfa-dihydrotestosterone and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in rat prostate. Biochem Biophys Acta 308: 426
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner TJ, Drago J, Wettlaufer J, Glode LM (1986) Androgen priming and response to chemotherapy in advanced prostatic cancer. J Urol 136: 1242
Pousette A, Bjork P, Carlstrom K, Forsgren B, Hogberg B, Gustafsson JA (1981) Influence of sex hormones on prostatic secretion protein, a major protein in rat prostate. Cancer Res 41: 688
Slack NH, Brady MF, Murphy GP and Investigatiors in National Prostatic Cancer Project (1984) A reexamination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer 54: 564
Suarez AJ, Lamm DL, Radwin HM, Sarosdy M, Clark G, Osborne CK (1982) Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol 8: 261
Tew KD, Hartley B (1984) Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology (Suppl) 23 (6): 28
This study was partially supported by a grant of the Italian National Research Council, Special Project “Oncologia”, contract number 85.02188.44
About this article
Cite this article
Boccardo, F., Decensi, A., Guarneri, D. et al. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. Cancer Chemother. Pharmacol. 22, 172–174 (1988). https://doi.org/10.1007/BF00257317
- Prostate Cancer
- Cancer Research
- Median Survival
- Partial Response